Head and neck squamous cell carcinoma (HNSCC) exhibits significant genetic heterogeneity, characterized by a wide range of gene mutations and copy number variations. This heterogeneity leads to varying response rates to available treatments, including chemotherapy and immune checkpoint inhibitors, resulting in poor five-year survival rates for patients with advanced disease. 

Our lab focuses on elucidating the roles of frequently mutated genes (CASP8, HRAS, CYLD, KEAP1) in HNSCC DEVELOPMENT, their interactions with the TIME (tumor immune microenvironment), and their contributions to RESISTANCE against chemotherapy and immunotherapy. We aim to identify novel treatment strategies for HNSCC associated with these mutations. 

To achieve our objectives, we utilize high-throughput CRISPRi screening technology, next-generation sequencing, tissue engineering, preclinical mouse tumor models, and transgenic mutation knock-in models, in conjunction with analyses of clinical patient samples. Our ultimate goal is to develop novel targeted therapeutic approaches that effectively address the challenges of treating advanced HNSCC that is resistant to conventional therapies.